174 related articles for article (PubMed ID: 37685961)
1. Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway.
Stukas D; Jasukaitiene A; Bartkeviciene A; Matthews J; Maimets T; Teino I; Jaudzems K; Gulbinas A; Dambrauskas Z
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685961
[TBL] [Abstract][Full Text] [Related]
2. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
[TBL] [Abstract][Full Text] [Related]
3. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
Dash S; Ueda T; Komuro A; Honda M; Sugisawa R; Okada H
Cell Death Dis; 2024 Feb; 15(2):131. PubMed ID: 38346958
[TBL] [Abstract][Full Text] [Related]
4. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
6. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
Dash S; Ueda T; Komuro A; Amano H; Honda M; Kawazu M; Okada H
Mol Cancer Res; 2023 May; 21(5):444-457. PubMed ID: 36757299
[TBL] [Abstract][Full Text] [Related]
7. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
[TBL] [Abstract][Full Text] [Related]
8. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
[TBL] [Abstract][Full Text] [Related]
10. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
Xiong J; Altaf K; Ke N; Wang Y; Tang J; Tan C; Li A; Zhang H; He D; Liu X
Medicine (Baltimore); 2016 Mar; 95(10):e2936. PubMed ID: 26962792
[TBL] [Abstract][Full Text] [Related]
11. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
12. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
13. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
Williams TK; Costantino CL; Bildzukewicz NA; Richards NG; Rittenhouse DW; Einstein L; Cozzitorto JA; Keen JC; Dasgupta A; Gorospe M; Gonye GE; Yeo CJ; Witkiewicz AK; Brody JR
PLoS One; 2010 Nov; 5(11):e15455. PubMed ID: 21152064
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
15. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
Zhou H; Telonis AG; Jing Y; Xia NL; Biederman L; Jimbo M; Blanco F; Londin E; Brody JR; Rigoutsos I
Cell Death Dis; 2016 Jul; 7(7):e2294. PubMed ID: 27415424
[TBL] [Abstract][Full Text] [Related]
16. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
17. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Zhang X; Zhao P; Wang C; Xin B
Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
[TBL] [Abstract][Full Text] [Related]
18. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
Maréchal R; Van Laethem JL
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1439-41. PubMed ID: 19828005
[TBL] [Abstract][Full Text] [Related]
19. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
[TBL] [Abstract][Full Text] [Related]
20. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
